Dual-Targeted Therapy in Cardiometabolic Risk: A Meta-Analysis of Telmisartan-Based Combinations for Hypertension and Dyslipidemia.

ABSTRACT:

Background

Hypertension often coexists with dyslipidemia, requiring combination therapy. Telmisartan, combined with amlodipine or rosuvastatin, targets these conditions. This meta-analysis evaluates the efficacy and safety of these combinations in adults with hypertension and dyslipidemia.

Methods

A systematic search was conducted in Cochrane Central, MEDLINE/PubMed, ClinicalTrials.gov, and ScienceDirect (as of June 2024) for randomized controlled trials (RCTs) comparing telmisartan plus amlodipine versus telmisartan plus rosuvastatin in adults (≥ 18 years) with hypertension and dyslipidemia. A random-effects model was used with RevMan 5.4.1. The risk of bias and heterogeneity were assessed with the Cochrane Risk of Bias Tool and the I² statistic.

Results

Three RCTs i

SUBMITTER: Asim R 

PROVIDER: S-EPMC12647966 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature